According to company, this approval of Wellbutrin XL in seasonal major depressive illness represents company’s third notice of compliance in the past six months. Biovail Pharmaceuticals Canada (BPC), the Canadian sales and marketing division of the company will introduce this new indication to Canadian health care professionals in 2008.
Scott Smith, vice-president and general manager of BPC, said: “Seasonal major depressive illness is a serious and often under-diagnosed type of depression. The approval of Wellbutrin XL as a prevention for this type of depression offers new hope to patients who dread the onset of winter, and the episodes of major depression that often come with it.”